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a  b  s  t  r  a  c  t
The  rise  in genomic  knowledge  over  the  past  decade  has revealed  the  molecular  etiology  of many  dis-
eases,  and  has  identiﬁed  intricate  signaling  network  activity  in  human  cancers.  Genomics  provides  the
opportunity  to determine  genome  structure  and  capture  the  activity  of thousands  of  molecular  events
concurrently,  which  is important  for deciphering  highly  complex  genetic  diseases  such  as cancer.  In this
review,  we focus  on  genomic  efforts  directed  towards  one  of  cancer’s  most  frequently  mutated  networks,
the RAS  pathway.  Genomic  tools  such  as  gene  expression  signatures  and  assessment  of mutations  across
the RAS  network  enable  the capture  of  RAS  signaling  complexity.  Due  to this  high  level  of interaction
and  cross-talk  within  the  network,  efforts  to target  RAS  signaling  in  the  clinic  have  generally  failed,  and
we  currently  lack  the  ability  to directly  inhibit  the  RAS  protein  with  high  efﬁcacy.  We  propose  that  the
use  of  gene  expression  data  can  identify  effective  treatments  that  broadly  inhibit  the  RAS  network  as
this  approach  measures  pathway  activity  independent  of  mutation  status  or any  single  mechanism  of
activation.  Here,  we  review  the  genomic  studies  that  map  the  complexity  of  the RAS  network  in  cancer,
and  that  show  how  genomic  measurements  of  RAS  pathway  activation  can  identify  effective  RAS  inhibi-
tion  strategies.  We  also  address  the  challenges  and  future  directions  for  treating  RAS-driven  tumors.  In
summary,  genomic  assessment  of RAS  signaling  provides  a level  of  complexity  necessary  to accurately
map  the network  that  matches  the  intricacy  of  RAS  pathway  interactions  in  cancer.
©  2016  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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. Introduction
High-throughput genomic analysis has beneﬁtted the study of
ignal transduction over the past decade [1]. Genomic sequencing
echniques are now routinely used in many research laborato-
ies, and are steadily becoming adopted in clinical settings [2].
he scientiﬁc community has used these technologies to better
nderstand the genetic basis of many human diseases, to help
iagnose disease and predict disease progression, and to pioneer
ersonalized healthcare initiatives [3,4]. Cancer is one of the dis-
ases that has been impacted greatly by the implementation of
enomics [4]. Large-scale cancer sequencing projects have allowed
s to view the cancer genome using multiple genomic proﬁling
trategies including whole-genome and transcriptome sequencing,
roteomics, genome-wide DNA methylome analysis, and DNA copy
umber analysis, all collectively deﬁned as “omics” [5–7]. These
trategies have reshaped how we view the cancer genome and have
hown that individual tumors harbor their own  unique genetic
akeup containing mutations, copy number changes, epigenetic
odiﬁcations, and aberrant expression of hundreds to thousands
f genes; therefore highlighting that multidimensional genomic
ata contributes to understanding cancer [5,8]. Genomics has been
uccessfully applied to oncology in many different contexts [1,9]
ncluding the identiﬁcation of cancer subgroups such as the intrin-
ic subtypes in breast cancer [10–12], the development of breast
ancer prognostic tools such as Oncotype DX and MammaPrint
o predict the risk of cancer recurrence [13], and the identiﬁca-
ion of KRAS mutations as predictors of poor drug response in lung
ancer [14]. Although approximately 140 driver mutations have
een discovered in human cancer, most of these mutations con-
erge on roughly 12 pathways that regulate three vital cellular
rocesses: cell growth, cell survival, and genome maintenance [8].
hus, tumors tend to rely on a subset of signaling phenotypes to
aintain growth and survival.
The RAS pathway is one of the most frequently dysregulated
athways in cancer, with approximately 30% of all patient tumors
xpressing activating RAS gene mutations [15]. Of the three main
soforms of oncogenic RAS, KRAS is the most frequently mutated,
ffecting ∼90% of pancreatic cancers, ∼35% of colon cancers, and
18% of lung cancers, while NRAS is mutated in ∼15% of melanomas,
nd HRAS is rarely mutated in cancer [16]. Aberrations in RAS genes
hemselves contribute to RAS pathway activation, but aberrations
f genes up- and downstream of RAS can also activate the pathway
Fig. 1), highlighting the need for genomics to broadly measure RAS
athway activation [17]. Cancers with RAS gene mutations are asso-
iated with drug resistance, poor prognosis, shorter survival, and
nhanced metastasis [18–23]. Extensive efforts have been made
owards the development of RAS protein inhibitors but, to date,
o effective direct RAS inhibitors are available in the clinic. Thus,
argeting this pathway effectively has a high potential for patient
eneﬁt.In this review, we discuss the role that genomics plays in deci-
hering the RAS signaling network and its mediators and how the
se of genomics has led to a better understanding of RAS network
omplexity. Also, as omic-level measurement captures RAS activity . . .  . . .  . . .  . .  .  . . . .  . . .  . .  . . .  . . . . .  . . . . .  .  . .  .  . . . .  .  . .  . . .  .  .  .  . .  . . . . .  . . . . .  .  .  .  .  . .  .  .  .  .  .  . 115
in both RAS-mutant and RAS-wild type tumors, these approaches
may  enable identiﬁcation of novel RAS pathway inhibitors not spe-
ciﬁc to mutant RAS. Overall, we expect genomics will continue to
lead to discoveries that will aid in the treatment of RAS-driven
cancers in the near future.
2. Genomics provides insight into the RAS pathway
2.1. Why  study RAS at the genomic level?
The RAS pathway is an intricate signaling cascade consisting
of numerous up- and downstream proteins and interconnected
pathways [24]. Due to the complexity of this pathway, a genomics
framework is necessary in order to study its activities concurrently
as a network. While extracellular growth signals normally activate
the RAS pathway, in cancer, activating mutations in RAS path-
way genes lead to sustained pathway signaling, resulting in the
aberrant activation of downstream oncogenic processes such as
cellular proliferation, cell survival, metabolic changes, and metas-
tasis [22,25–29]. The RAS pathway is not linear and can activate
multiple downstream pathways such as the RAF/MEK/ERK path-
way, the phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway,
and the RAL-GDS pathway, all leading to various oncogenic events.
Adding further complexity, RAS can activate additional proteins
including AF-6, CANOE, TIAM1, MEKK1, p120GAP, NF1, RIN1, PKC-
, and NORE1, illustrating the far-reaching roles of RAS [30]. In
cancer, the RAS pathway can become activated by aberrations in
either upstream growth factor receptors such as EGFR and IGF1R,
or in downstream pathway proteins such as GAPs, GEFs, RAF, MEK,
and ERK, by loss of function of RAS negative regulators (SPRY,
SPRED, DUSPs, RASA1, NF1), and through activation of alterna-
tive pathways (PI3K, PTEN, RALGDS, MEKK1) [25,27,31–35] (Fig. 1).
Therefore, the RAS pathway is a complex network requiring a
genomic approach that matches that complexity.
2.2. Genomics shows dysregulation of RAS pathway components
across cancers
The availability of genomic sequencing has enabled the mass
proﬁling of various cancer types using multi-omic data [7]. One
such effort has been pioneered by The Cancer Genome Atlas
research network (TCGA), a large international research effort that
has produced omic data for over twenty different cancers, includ-
ing both DNA- and RNA-sequencing for over 11,000 tumors [36].
Here, we  highlight the spectrum of RAS pathway aberrations from
the TCGA’s ﬁndings in several cancer types including lung adeno-
carcinoma, colorectal carcinoma, and head and neck squamous cell
carcinoma (HNSCC).
Upon proﬁling colorectal carcinoma, the TCGA found that 55%
of non-hypermutated colorectal carcinomas, a molecular subtype
accounting for 84% of the studied samples, demonstrated KRAS,
NRAS, or BRAF alterations; mutations in these genes were found
to be signiﬁcantly mutually exclusive [37]. Interestingly, the TCGA
also found a co-occurrence of RAS pathway and PI3K pathway
mutations in one-third of colorectal tumors, indicating the need
110 G. Shrestha et al. / Seminars in Cell & Developmental Biology 58 (2016) 108–117















rig. 1. RAS pathway aberrations in human cancers. The RAS pathway can be activat
roteins are both mutated and overexpressed (red). Dysregulation can occur in dow
he  loss of function of RAS regulators such as GAPs (yellow).
o target both pathways to effectively inhibit tumor growth in
ancers of this type. Furthermore, genomic analysis of lung ade-
ocarcinoma revealed that 62% of these cancers bear a canonical
ncogenic driver mutation in the RAS/RAF/MEK pathway [38]. Upon
xpanding this analysis to include focal ampliﬁcations of upstream
eceptor tyrosine kinases (RTKs), as well as loss of function muta-
ions in tumor suppressor genes in the RAS pathway, such as NF1,
he number of lung adenocarcinomas with driver mutations in the
AS pathway increased to 76%. Importantly, this study also used
everse phase protein array (RPPA) data to demonstrate that both
RAS-mutant lung adenocarcinoma samples and a subset of KRAS-
ild type samples exhibited high MAPK pathway activity. These
esults highlight the importance of understanding pathway-levelmutation (green) or by overexpression (blue) of pathway proteins. In some cancers,
am effector molecules including RAF, MEK, PI3K, and AKT. RAS is also activated by
activation beyond single gene mutational status when assessing a
tumor’s dependency on a pathway for survival. Subsequent inves-
tigation of HNSCC demonstrated that in this cancer type, 5% of
HPV-negative cancers contain an HRAS mutation [39]. It is impor-
tant to note, however, that the study also found mutation or
ampliﬁcation in EGFR (15% of HPV-negative samples), FGFR1 (10%),
ERBB2 (5%), IGF1R (4%), and several other RTKs (3% or less), thus
contributing to a wider spectrum of RAS pathway aberrations than
HRAS mutation alone. Therefore, by implementing whole-genome
sequencing, the TCGA research network conﬁrmed the high preva-
lence of somatic mutations and ampliﬁcations contributing to RAS
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Publically available TCGA datasets have also enabled further dis-
overies that have provided additional insight into RAS pathway
berrations. For example, Raphael and Fabio developed a path-
ay linear progression model to determine the temporal order of
omatic driver mutation in key pathways during oncogenesis [40].
sing the TCGA colorectal cancer dataset, they showed that muta-
ions in the RAS pathway occur late in tumorigenesis–mutations
n APC or FBXW7 and either TP53 or PIK3CA generally occur before
embers of the RAS pathway are mutated in colorectal cancers.
imilarly, Want et al. integrated the TCGA breast cancer data
onsisting of somatic mutations, copy number variations, transcrip-
omics, and DNA methylomics, into “risk pathways” by mapping
lterations in genes at each tested omic level to pathways in
he Kyoto Encyclopedia of Genes and Genomes (KEGG) to deter-
ine pathways altered in breast cancer [31]. Additionally, these
isk pathways were constructed into pathway cross-talk networks
ased on protein–protein interaction data from the Human Pro-
ein Reference Database (HPRD). Want et al. identiﬁed KRAS as a
ajor connector between multiple risk pathways, thus supporting
he importance of targeting RAS dependence as a signiﬁcant ther-
peutic opportunity [31]. Thus, not only has TCGA genomic data
rovided unprecedented insight into the omic landscape of can-
er, it has also enabled a broader understanding of both mutational
rogression during oncogenesis and of pathways dysregulated in
ancers.
.3. Gene expression signatures can quantify RAS network activity
ndependent of the mechanism by which the pathway is activated
A gene expression signature is deﬁned as a group of genes whose
ombined expression patterns are uniquely characteristic of a bio-
ogical phenotype, or in the context of this review, a biological
athway [9]. In the early 2000s, researchers began developing gene
xpression signatures to predict the activity of various oncogenic
ignaling pathways using microarray data [3,41,42]. Gene expres-
ion signatures have the capability to measure cellular signaling
vents because whether or not the signaling event directly mod-
lates transcription factors, cellular signaling eventually results in
ene-expression changes [43]. Understanding that the RAS path-
ay could be activated by RAS gene mutations, or by multiple other
echanisms, led researchers to generate RAS gene expression sig-
atures as a method to better determine RAS pathway activation
42].
One of the ﬁrst RAS-speciﬁc gene expression signatures was
enerated by overexpressing the Hras gene in mouse embryonic
broblast cells using recombinant adenoviruses [44]. This signature
ccurately reﬂected the activation state of Hras, acting as a proof of
rinciple that overexpressing oncogenes in cells could result in spe-
iﬁc gene expression changes, which could then represent speciﬁc
athway activity [44]. An additional RAS gene expression signature
as derived by Sweet-Cordero et al. [45] from a sporadically-
ctivated Kras2 mouse model. This signature was generated by
omparing gene expression differences between activated Kras2
umors and normal lung tissue, was validated, and was  able to
redict KRAS activity in lung adenocarcinoma, a RAS-activated can-
er. This approach suggested that signatures generated in mouse
umors could accurately reﬂect human biology, and provided a
trategy for using genomic analysis of animal models to probe
uman disease [45].
Bild et al. [46] built upon the work of Huang et al. [44] by generat-
ng a pathway-based gene expression signature by overexpressing
utant HRAS in human primary epithelial cells. The group usedupervised clustering to generate gene expression changes indica-
ive of RAS pathway activation. This signature accurately predicted
AS pathway activation in mice and human tumors with RAS muta-
ions, such as human non-small cell lung carcinoma. Interestingly,pmental Biology 58 (2016) 108–117 111
the study found that higher RAS pathway activity correlated with
decreased survival in lung cancer.
Chang et al. also developed a novel approach for utilizing gene
expression signatures by deconstructing RAS gene expression sig-
natures into “modules,” which represent smaller components of
the pathway [47]. This study found that particular modules from
the RAS gene expression signature were able to distinguish high-
and low-risk survival groups in lung adenocarcinoma better than
using the entire gene expression signature. These results further
demonstrate the beneﬁts of using gene expression signatures to
deconstruct and better understand the RAS network. Other impor-
tant uses of RAS gene expression signatures include, but are not
limited to, the prediction of RAS activity in gastric cancer by Ooi
et al. [48], and the generation of a “KRAS dependency” signature
in lung cancer by Singh et al. [49]. Overall, methods for using
gene expression signatures to measure RAS pathway activity tran-
scend the traditional use of single genes to measure RAS activation,
which, as shown here, does not always represent pathway activity
[3].
2.4. KRAS, EGFR, and RAF gene expression signatures show RAS
pathway complexities across multiple cancers
Genomics has facilitated the understanding that many different
RAS pathway components contribute to RAS pathway activation,
and that RAS mutations do not always correlate with activation
of the pathway [46,50,51]. This illustrates the need for higher
level genomic measurements of the RAS pathway. To further
explore pathway activation in relation to mutational status, we
measured pathway activity and mutational status for key RAS
pathway components EGFR, KRAS, and RAF across 8 different can-
cers in TCGA [6] which express varying levels of KRAS, EGFR, or
BRAF mutations. Speciﬁcally, we used our previously generated
gene expression signatures that measure the activity of the EGFR,
KRAS, and RAF1 pathway components using our published pathway
modeling toolkit, Adaptive Signature Selection and InteGratioN
(ASSIGN) [46,52,53] (see Methods section). Unsupervised hierarchi-
cal clustering of the pathway activity estimates for all cancer types
and pathway signatures revealed distinct patterns of pathway acti-
vation across cancer types (Fig. 2). The pathway activity for EGFR,
KRAS, and RAF1 and mutational status for KRAS (pink), BRAF (blue),
and EGFR (green) for each TCGA cancer and patient are represented
in Fig. 2 for (A) head and neck squamous cell carcinoma, (B) rectum
adenocarcinoma, (C) uterine carcinoma, (D) lung adenocarcinoma,
(E) ovarian serous cystadenocarcinoma, (F) breast invasive carci-
noma, (G) bladder urothelial carcinoma, and (H) kidney renal clear
cell carcinoma.
To illustrate the ability of gene expression signatures to accu-
rately predict pathway activation in patient tumors, we highlight
situations in which gene mutations complement pathway acti-
vation. For example, 81% of all rectum adenocarcinoma patients
harboring KRAS mutations also have high KRAS activation scores
(Fig. 2B). We  also found high EGFR activation scores (51% of
patients) in head and neck squamous cell carcinoma (Fig. 2A), a
cancer in which EGFR is known to be overexpressed [54], and lung
adenocarcinoma (44% of patients), a cancer with high EGFR muta-
tion rates (Fig. 2D). While gene mutations are generally reﬂective
of pathway activation, there were cases in which gene mutational
status did not alone correlate with activation of the pathway. For
example, in lung adenocarcinoma, a known RAS-driven cancer sub-
type, a high proportion of patients have RAS pathway activation
independent of mutation status (Fig. 2D). We observed additional
instances in which gene mutations were not found, but the path-
ways were activated. For example, in bladder urothelial carcinoma
(Fig. 2G), only 3 patients had EGFR mutations, and no mutations
were found in KRAS or RAF, but pathway activation was found in
112 G. Shrestha et al. / Seminars in Cell & Developmental Biology 58 (2016) 108–117










sC)  uterine carcinoma, (D) lung adenocarcinoma, (E) ovarian serous cystadenocarc
enal  clear cell carcinoma. Red values indicate high pathway activity and blue repre
n  KRAS (pink), EGFR (light blue), and BRAF (green). Black bars in gene columns indi
2%, 22%, and 38% of cases for EGFR, KRAS, and RAF pathways,
espectively, thus highlighting that the absence of mutations does
ot always mean the pathway is inactivated. Few mutations and
igh pathway activation were also observed in breast invasive
arcinoma (Fig. 2F), kidney renal clear cell carcinoma (Fig. 2H),
nd ovarian serous cystadenocarcinoma (Fig. 2E). These results
upport the idea that pathway activation can occur due to othera, (F) breast invasive carcinoma, (G) bladder urothelial carcinoma, and (H) kidney
w pathway activity. Color bars on the right side represent different gene mutations
resence of mutations.
mechanisms such as mutations or ampliﬁcations in other genes
or crosstalk/compensation within the RAS pathway [55]. Using
expression signatures to measure pathway activity, we  also found
that each cancer had its own unique and heterogeneous pattern of
EGFR, KRAS, and RAF1 activation (Fig. 2B–H). Overall, these results
demonstrate how the use of multiple mechanisms to measure path-



























































a speciﬁc network [50]. Of note, the above-mentioned resultsG. Shrestha et al. / Seminars in Cell & 
utation status. These results also show how the complexity of
ignaling network interactions in tumors cannot be generalized to
ll cancer types.
. The impact of genomics on RAS pathway driven cancer
herapeutics
.1. Genomics helps guide the use of targeted therapies towards
AS pathway components
Since the initial characterization of RAS as an oncogene in 1982,
56,57] various initiatives have been taken to target RAS genes,
roteins, and, more recently, downstream members of the RAS
athway. For example, in the early 1990s, researchers attempted
o target RAS proteins directly with small molecule inhibitors and
ith farnesyltransferase inhibitors (FTIs) [58]. While FTIs efﬁciently
nhibited farnesylation in HRAS mutant cancers [59,60], they failed
o show efﬁcacy in KRAS and NRAS mutant cancers as these iso-
orms can undergo alternative methods of membrane association
61]. Similarly, attempting to directly target the guanine nucleotide
inding site of RAS using small molecule inhibitors failed due to the
rotein’s lack of allosteric regulatory sites and its picomolar afﬁnity
or GTP [62]. Therefore, few effective treatment options are cur-
ently available for patients with RAS-driven cancers, which has led
o the characterization that RAS is “undruggable” [63,64]. However,
ecent studies have identiﬁed compounds capable of either bind-
ng to mutant RAS proteins directly or interfering with RAS’s ability
o bind to the guanine nucleotide exchange factor Son of Sevenless
SOS) [65–68]. Nevertheless, these novel RAS-targeting compounds
equire further development before they can be implemented into
linical trials.
The discovery of RAS effector proteins and recurrent onco-
enic mutations in downstream RAS pathway components (BRAF,
EK, ERK, and PI3K pathway members) [69–72], led to the devel-
pment of several inhibitors including sorafenib, vemurafenib,
nd dabrafenib for RAF-mutated cancers, and trametinib and
obimetinib for MEK-mutated cancers [26,73]. More recently, ERK
nhibitors and PI3K pathway inhibitors, such as the FDA-approved
I3K inhibitor idelalisib, have also been developed [74–76]. Com-
ination treatments targeting the RAF/MEK/ERK pathway and PI3K
athway are now under different phases of clinical evaluation in
arious advanced solid tumors [77–79].
Measuring the mutational status of RAS pathway genes has pro-
ided clinical beneﬁts such as guiding the use of targeted therapies,
nd selecting appropriate patient populations for clinical trials in
articular cancers. For example, KRAS mutations are indicative of
esistance to anti-EGFR therapies [80,81], and BRAF V600E muta-
ions are indicative of response to RAF inhibitors [82]. However,
etermining the mutational status of speciﬁc genes is not always
eneﬁcial for predicting drug response, as mutations do not always
orrelate with pathway activation [46,50]. For instance, only 53%
f patients with BRAF V600E mutations demonstrate partial or
omplete response to the RAF inhibitor, vemurafenib [83]. Cancers
arrying mutations in the RAS pathway are not always dependent
n RAS signaling, and the absence of RAS gene mutations does not
lways correlate with RAS inactivity as additional components of
he network may  be activated [41,49]. For example, absence of
egative-feedback regulators, such as Sprouty (SPRY) and Sprouty-
elated (SPRED), and RAS GAPs such as NF1, can also activate the
AS pathway in various cancers [32,84]. These studies support the
otion that treatment decisions based solely on RAS mutational
nalysis may  overlook a large population of patients not carrying
AS mutations, but have RAS pathway activation.pmental Biology 58 (2016) 108–117 113
3.2. Gene expression signatures aid in predicting response to
targeted therapies in RAS-driven cancers
Previously, several groups have demonstrated that RAS gene
expression signatures are capable of measuring RAS pathway
activation [44–46]. In addition, gene expression signatures can
also be used to predict drug response to RAS inhibitors. For
example, breast cancer cell lines with high RAS pathway activ-
ity responded better to RAS farnesyltransferase inhibitors than
cell lines with low RAS pathway activity [46]. The ability to pre-
dict drug response in cell lines engendered the idea that gene
expression signatures may  be capable of predicting response to
targeted therapies in patients [85]. Loboda et al. [51] also used
gene expression signatures to predict response to PI3K and RAS
pathway inhibitors using a different approach that leveraged RAS
gene expression signatures from multiple datasets [45,46,86] to
create a comprehensive RAS gene expression signature. Not only
was this signature predictive of KRAS mutation status in lung
tumors and cell lines, but also it was  superior to KRAS mutation
status for predicting RAS signaling dependence and drug response
[51].
Dry et al. [87] was the ﬁrst to develop gene expression signa-
tures capable of predicting MEK  addiction and drug response to a
MEK  inhibitor, selumetinib, in a large panel of diverse cell lines.
These gene expression-based signatures were able to predict drug
response in multiple cancer types and xenograft mouse models
and provided a useful tool for studying MEK  biology and applica-
tion of MEK  inhibitors [83]. Similarly, Tentler et al. [88] also used
gene expression-based signatures to predict response to selume-
tinib in KRAS-mutant colorectal cancer (CRC) using both in vitro
and xenograft models. This study identiﬁed 3 gene pairs (PEG10
& CYBRD1, CALB1 & NELL2, and SKAP1 & MIA) which predicted
the response to selumetinib with 86% accuracy in an indepen-
dent set of 14 KRAS mutant CRC cell lines. This study further
validated these 3 gene pairs in human CRC explants with 71% accu-
racy.
With the knowledge that RAS pathway gene expression signa-
tures can predict RAS signaling dependence more effectively than
KRAS mutations alone, Tian et al. [89] analyzed gene expression
patterns from a large number of patients with colorectal cancer
and built a model for identifying activated EGFR signaling. This sig-
nature consisted of a combination of mutational signatures from
patients with KRAS, BRAF, and PIK3CA mutations and characterized
response to the EGFR inhibitor cetuximab. This study highlighted
the use of combining multiple gene expression signatures together
from various nodes in the same pathway to identify which patients
will beneﬁt from pathway inhibition [89].
Recently, El-Chaar et al. [50] used the Bild et al. RAS signa-
ture [46] to develop a network-based genomic framework for
drug discovery. El-Chaar et al. projected the RAS signature into
non-small cell lung cancer (NSCLC) cell lines to determine RAS
pathway activation, then treated cell lines with targeted drug
regimens along with a panel of 366 novel compounds. Results
showed that combined inhibition of EGFR and MEK  was  effec-
tive at inhibiting RAS pathway-active cancer cells. Also, KRAS
pathway activation accounted for the responsiveness to the com-
bined EGFR/MEK inhibition, rather than KRAS mutation status
alone, further highlighting the problems with relying on single
genes to predict drug response. These results further illustrate
the beneﬁts of using genomic signatures to characterize onco-
genic pathways in cancer, and to ﬁnd drugs that target and inhibitrequire further research to explore whether the gene expression-



























































We  adjusted the batch effects within and between the signa-
tures and TCGA gene expression data using the “ComBat” function
from the R package sva (version 3.16.1) [100,101]. ComBat was run
using the reference-batch option, which adjusts the data to match
an indicated batch. We  selected the sequencing batch containing14 G. Shrestha et al. / Seminars in Cell & 
. Conclusion and future prospects
The RAS network is large and complex and consists of many
nterconnecting pathways that play a major role in cellular growth,
vasion of apoptosis, and metastasis [33]. Cancers reliant on RAS
ignaling for survival are often aggressive and treatment options
re limited [90]. RAS-driven tumors are challenging to treat due to
he difﬁculties of measuring RAS-related signaling events in tumors
46], the current inability to directly target RAS proteins [91], and
he inevitable development of drug resistance to targeted thera-
ies [92]. Here, we have reviewed genomic studies showing that
he RAS pathway can become activated by dysregulation of multi-
le nodes of the network and that gene expression and mutation
ignatures can be used to measure activation of the RAS network
ore broadly. We  also highlighted how these genomic tools can
redict drug response better than single genes, how genomics can
dentify drug strategies that target RAS, and how genomic data can
e used to determine the probability of patient response to ther-
py. Thus, these genomics-guided ﬁndings have the potential to
hange how we measure RAS activity and ﬁnd effective treatments
or RAS-driven cancers.
Although genomics methods do hold great promise in cancer,
t is also important to note some of the drawbacks and contin-
ed challenges inherent to these methods. In relation to gene
xpression signatures to guide drug response, clinical relevance
equires clinical trials and analytical testing to validate their ben-
ﬁt [9]. Therefore, gene expression signatures will need to be
ade into clinically-relevant biomarkers, similar to OncotypeDX
nd MammaPrint in breast cancer [93]. Another important point
s that pathways function differently depending on the cell type,
peciﬁc genomic alteration, and organism [94]. For example, BRAF
nhibitors work well in melanomas harboring mutations in the BRAF
ene, but have no therapeutic effect in colorectal cancer patients
arboring the identical BRAF mutations, due to PI3K/AKT activation
ommon in colorectal cancers [95,96]. This highlights the dangers
f generalization and the need to measure activation of the various
AS pathway nodes concurrently in individual patients.
Lastly, we would like to note that the use of genomics to cap-
ure changes in RAS network activity broadly over time will enable
s to combat development of drug resistance. Current methods to
ssess a patient’s response to therapy, including imaging or blood
ests, fail to personalize treatment regimens after drug resistance
as been identiﬁed. We  propose that measuring RAS pathway acti-
ation using genomics prior to time points when standard clinical
ests such as computerized tomography (CT) scans are action-
ble will enable “real time” assessment of resistance mechanisms.
mportantly, identiﬁcation of the mechanisms of acquired resis-
ance to drug inhibitors of this network, which will be feasible
sing genomics, will help us adapt therapy strategies to match the
ynamic nature of cancer.
Overall, genomics has contributed greatly to the understand-
ng of cancer, including RAS-driven cancers [5]. We  anticipate that
enomic discoveries will continue to improve our understanding of
he RAS signaling network and inform new strategies for managing
reatments, and that in the near future, RAS-driven tumors may  no
onger be considered “undruggable.”
. Methods
.1. EGFR, KRAS (G12V), and RAF1 gene-expression proﬁling dataEGFR, KRAS (G12V), and RAF1 were overexpressed in primary
uman mammary epithelial cells (HMECs) using recombinant ade-
oviruses as detailed by Bild et al. and Rahman et al. [46,53,97].
ells were incubated with virus for 18 h except for KRAS (G12V),pmental Biology 58 (2016) 108–117
which was incubated for 36 h. KRAS virus was  obtained from Vec-
tor Biolabs, RAF1 from Cell Biolabs, and EGFR was a gift from
Duke University. To validate that infections worked and pro-
teins were overexpressed we extracted protein from EGFR, KRAS
(G12V), and RAF1 overexpressing cells and compared to GFP con-
trols using western blotting methods described by Bild et al. and
Rahman et al. [46,53]. HMECs were probed with the following
primary antibodies: EGFR (#4267), pEGFR (#2234), KRAS (sc-30),
pMEK (#9154), p-cRAF (#9427), GAPDH (#5174), and -tubulin
(#2146). All antibodies were obtained from Cell Signaling Technol-
ogy, besides KRAS, which was  from Santa Cruz. RNA was extracted
using methods by Rahman et al. [97]. cDNA libraries were prepared
from extracted RNA using the Illumina Stranded TruSeq proto-
col (Illumina). cDNA libraries were sequenced at Oregon Health
and Sciences University using the Illumina HiSeq 2000 sequencing
platform with six samples per lane. Single-end reads of 101 base
pairs were generated. Log2TPM gene expression data for the EGFR,
KRAS (G12V), and RAF1 pathways were all processed using meth-
ods described by Rahman et al. [53,97]. This data is available on
Gene Expression Omnibus (GEO), accession numbers: GSE83083
can be accessed at http://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc=GSE83083 for RAF1 and KRAS (G12V), and GSE59765 for
EGFR.
5.2. The cancer genome atlas (TCGA) data
All TCGA gene expression data was obtained from GEO acces-
sion number GSE62944 [97]. TCGA gene mutation data for EGFR,
BRAF, and KRAS was downloaded from CbioPortal [98]. Any muta-
tions found in KRAS, EGFR, or BRAF were included on heatmaps. We
only included TCGA samples which had both gene expression and
mutation data. The following TCGA data sets were used: head and
neck squamous cell carcinoma, rectum adenocarcinoma, uterine
carcinoma, lung adenocarcinoma, ovarian serous cystadenocarci-
noma, breast invasive carcinoma, bladder urothelial carcinoma, and
kidney renal clear cell carcinoma.
5.3. Generation of gene expression signatures
We  used Adaptive Signature Selection and InteGratioN (ASSIGN;
Version 1.7.2), to generate gene expression signatures. A formal
deﬁnition of the ASSIGN model and software implementation was
previously described [52]. RNA-Seq data from HMECs overexpress-
ing GFP control were compared to HMECs overexpressing KRAS
(G12V), RAF1, and EGFR. ASSIGN uses a Bayesian variable approach
[99] to select genes with the highest weights and signal strengths,
indicating differential expression. These genes represent oncogenic
signatures, and are also found in Rahman et al. [53].
5.4. Batch adjustment of gene expression signatures and TCGA
dataRAF1 as the reference batch. Additionally, we  adjusted for back-
ground baseline gene expression differences between oncogenic
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.5. Optimization of single-pathway estimates in TCGA BRCA
atient data
To determine the optimum number of genes for each onco-
enic signature, we generated signatures with gene lists lengths
rom 25 to 500 genes, in 25 gene increments in breast cancer,
sing ASSIGN’s single pathway settings. For all of the signatures that
assed internal leave-one-out-cross-validation, pathway estimates
ere included for further validation in mutation, gene expression,
nd proteomics data all described by Rahman et al. [53].
.6. ASSIGN for all other cancers
We  applied optimized gene expression signatures to head
nd neck squamous cell carcinoma (n = 504), rectum adenocarci-
oma (n = 167), uterine carcinoma (n = 57), lung adenocarcinoma
n = 541), ovarian serous cystadenocarcinoma (n = 429), breast inva-
ive carcinoma (n = 1119), bladder urothelial carcinoma (n = 414),
nd kidney renal clear cell carcinoma (n = 542) to generate path-
ay predictions using ASSIGN. Pathway predictions generated by
SSIGN are represented as values from zero to one. Values of zero
epresent no pathway activity, and values of one represent high
athway activity. We  adjusted for the variation in magnitude and
irection of signature-relevant gene expression between oncogenic
ignatures training samples and test samples using ASSIGN’s adap-
ive signature parameter. The code for running this analysis can be
ound at https://github.com/smacneil1/PANCAN24 Analysis.
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